Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing
Conclusion Personal or family history of breast or ovarian cancers is a feasible, cost-effective risk categorization for screening germlineBRCA mutations in Asian PDAC patients as 10% of this population had the pathogenic mutation herein. Future validation from a large, prospective cohort is needed.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Gastroschisis Repair | Genetics | Investigational New Drugs | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Study